Plain-English translation of NCT07560306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new imaging scan called [64Cu]FBP8 PET/MRI that is designed to detect blood clots inside the heart. The scan uses a special tracer that binds to clots, making them visible on the imaging machine. Researchers want to see if this new scan can accurately find blood clots in patients who have amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart) combined with irregular heartbeat.
Blood clots inside the heart can be serious and lead to stroke, especially in people with amyloid heart disease and irregular heartbeat. Currently, doctors use an invasive procedure called transesophageal echocardiography to look for these clots, but this new imaging scan could detect clots in a non-invasive way—meaning no procedure down the throat—and may help doctors catch and prevent serious complications.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo a [64Cu]FBP8 PET/MRI scan, which combines two imaging technologies to look for blood clots in your heart. This scan is non-invasive—you simply lie inside the scanner for a period of time while images are taken. The study will compare the results of your PET/MRI scan to results from your recent or upcoming esophageal ultrasound to see how accurate the new imaging method is.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States